Men's Health News

RSS

Priligy - new drug for premature ejaculation

For men suffering from premature ejaculation there may be a new savior in town. The new drug called Priligy is reported to triple the time a man can last in bed. It is currently not licensed in the UK, but is available and licensed for use in a number of other European countries.

28 Apr 2010

Reluctant Australian sperm donors forces fertility clinics to import from U.S.

With the shortage of sperm donors the Queensland Fertility Group, the largest fertility facility in Townsville has resorted to importing sperm from United States. This facility, some 1,300 Kilometers from Brisbane is reportedly paying $700-800 an ampule for the imported sperm. This is a new situation. Earlier the facility had a large number of donors of which a huge number were the university students but there has been a steady decline in donors with many north Queensland men, or even Australian men who are not prepared to donate.

27 Apr 2010

Patients with most severe form of prostatitis show signs for periodontitis: Researchers

Researchers from Case Western Reserve University School of Dental Medicine and University Hospitals Case Medical Center report initial results from a small sample that inflammation from gum disease and prostate problems just might be linked. They discuss their new evidence in the Journal of Periodontology, the official journal of the American Academy of Periodontology.

27 Apr 2010

Men with erectile dysfunction, low testosterone at higher risk of death from cardiovascular disease

Research presented at the European Congress of Endocrinology shows for the first time that men with erectile dysfunction and low testosterone have a higher than normal risk of dying from cardiovascular disease. Further work from the same research group shows that obesity is also associated with an impairment of blood flow to the penis, which in turn is also associated with cardiovascular disease in men with erectile dysfunction.

27 Apr 2010

Phase 1/2 clinical trial of TRC105 therapy initiated for patients with castrate-resistant prostate cancer

TRACON Pharmaceuticals, a biotechnology company that develops targeted therapies for oncology and ophthalmology, announced today that the National Cancer Institute has initiated a Phase 1/2 clinical trial of TRC105 therapy for patients with castrate-resistant prostate cancer.

26 Apr 2010

Personal risk of developing prostate cancer increases when more direct relatives are affected

For a long time now doctors have known that prostate cancer "runs in the family". Men with family members who have been diagnosed with the disease have an elevated risk of developing cancer of the prostate. But exactly how high is an individual person's risk? For whom and at what age should an early detection screening urgently be recommended?

24 Apr 2010

Insufficient evidence on prostate cancer radiation treatment

Reuters: "There is not enough evidence to sort out the effect of various radiation treatments for prostate cancer patients, especially newer, so-called focused radiation, an advisory panel told the U.S. Medicare agency on Wednesday.

23 Apr 2010

Better diagnostics in prostate cancer needed

A flurry of confusing research about the benefits of PSA testing has left many men and their physicians reticent to use a test that may be life-saving, says a panel of prostate cancer experts. The experts who gathered on Capitol Hill in Washington on Tuesday agreed that PSA testing, while not cancer-specific, is one of the best available tools for early detection of a cancer that kills 27,000 American men each year.

23 Apr 2010

RMEI, PIM jointly sponsor complimentary continuing education virtual lecture on CRPC

Castrate-refractory prostate cancer, which is characterized by tumor progression despite castrate levels of testosterone, develops in many prostate cancer patients treated with androgen-deprivation therapy. Standardized guidelines for the treatment of CRPC are lacking, and a number of factors must be considered when deciding between second-line hormonal therapy and chemotherapy.

23 Apr 2010

DiagnoCure's proprietary prostate cancer biomarker PCA3 presented at 2010 EAU meeting

DiagnoCure, Inc., a life sciences company commercializing high-value cancer diagnostic tests and delivering laboratory services, announced that its proprietary prostate cancer biomarker PCA3 was the topic of over 13 presentations at the 2010 European Association of Urology meeting, the world largest urology event, held in Barcelona, Spain, with 14,000 registrants.

22 Apr 2010

Gen-Probe's PROGENSA PCA3 assay helps determine necessity of initial biopsy in prostate cancer suspect men

Gen-Probe's PROGENSA® PCA3 assay can help predict the outcome of initial prostate biopsies in men suspected of having prostate cancer, according to a study of the molecular urine test presented in a scientific poster last week at the 25th annual European Association of Urology (EAU) Congress in Barcelona, Spain.

22 Apr 2010

CINJ researches identify new drug candidates that inhibits prostate cancer growth

Trying to break down a barrier that prevents effective treatment of prostate cancer, researchers from The Cancer Institute of New Jersey (CINJ) have identified candidate drugs that block a key protein responsible for tumor growth.

21 Apr 2010

Cold, dry weather linked to increased risk of prostate cancer: Researchers

Cold, dry weather has been linked to an increased incidence of prostate cancer. Researchers writing in BioMed Central's open access International Journal of Health Geographics suggest that meteorological effects on persistent organic pollutants, such as some pesticides and industrial by-products, may be to blame.

21 Apr 2010

IMPACT trial shows improvement in OS for metastatic CRPC

Dr. Neal Shore (GB) presented for the first time in Europe the updated results of the study "Sipuleucel-T Active Cellular Immunotherapy for Metastatic, Castration-Resistant Prostate Cancer: results from the IMPACT trial," during the second plenary session of the 25th Anniversary EAU Congress in Barcelona.

21 Apr 2010

Weight gain near time of prostate surgery doubles risk of cancer recurrence

Johns Hopkins epidemiologists say that prostate cancer patients who gain five or more pounds near the time of their prostate surgery are twice as likely to have a recurrence of their cancer compared with patients whose weight is stable.

20 Apr 2010

PTEN expression clinically useful in assessing risk of prostate cancer recurrence: Study

Myriad Genetics, Inc. today said results from a recent study indicate that expression of the PTEN gene may be clinically useful in assessing a man's risk of prostate cancer recurrence after radical prostatectomy.

20 Apr 2010

Encouraging early data from Bellicum Pharmaceuticals' Phase I/II study of BPX-101 for mCRPC

Bellicum Pharmaceuticals, Inc., a company developing therapeutic cancer vaccines, today announced the presentation of interim Phase I/II efficacy data for BPX-101, a novel dendritic cell vaccine for metastatic castrate resistant prostate cancer (mCRPC), in a Late Breaking poster at the American Association for Cancer Research (AACR) 101st Annual Meeting 2010 held in Washington, D.C.

19 Apr 2010

Debate continues over prostate cancer screening in Europe

The European Association of Urology reiterated that it does not recommend a mass screening policy in Europe for men who are concerned over prostate cancer, a stance which reflects the position it issued last year regarding prostate cancer screening. "We don't believe that the time has come for mass screening," said EAU Secretary General.

19 Apr 2010

Updated clinical guidelines presented at EAU Anniversary Congress

A number of updated guidelines are presented at the Anniversary Congress of the European Association of Urology (EAU) held in Barcelona, from 16 through 20 April. The abridged versions - Pocket Guidelines - which are based on the extended text documents will also be available in Barcelona to all EAU members and press.

17 Apr 2010

New drug to stop the growth of prostate cancer tumors investigated

The American Cancer Society estimates one man in six will get prostate cancer during his lifetime, making it the second-leading cause of cancer death in men. With a new partnership with Areva Med, UC researchers will investigate the use of a new drug in stopping the growth of prostate cancer tumors.

17 Apr 2010

Men's Health News

Priligy - new drug for premature ejaculation

Reluctant Australian sperm donors forces fertility clinics to import from U.S.

Patients with most severe form of prostatitis show signs for periodontitis: Researchers

Men with erectile dysfunction, low testosterone at higher risk of death from cardiovascular disease

Phase 1/2 clinical trial of TRC105 therapy initiated for patients with castrate-resistant prostate cancer

Personal risk of developing prostate cancer increases when more direct relatives are affected

Insufficient evidence on prostate cancer radiation treatment

Better diagnostics in prostate cancer needed

RMEI, PIM jointly sponsor complimentary continuing education virtual lecture on CRPC

DiagnoCure's proprietary prostate cancer biomarker PCA3 presented at 2010 EAU meeting

Gen-Probe's PROGENSA PCA3 assay helps determine necessity of initial biopsy in prostate cancer suspect men

CINJ researches identify new drug candidates that inhibits prostate cancer growth

Cold, dry weather linked to increased risk of prostate cancer: Researchers

IMPACT trial shows improvement in OS for metastatic CRPC

Weight gain near time of prostate surgery doubles risk of cancer recurrence

PTEN expression clinically useful in assessing risk of prostate cancer recurrence: Study

Encouraging early data from Bellicum Pharmaceuticals' Phase I/II study of BPX-101 for mCRPC

Debate continues over prostate cancer screening in Europe

Updated clinical guidelines presented at EAU Anniversary Congress

New drug to stop the growth of prostate cancer tumors investigated

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Latest News